
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Holdings Inc. is positioned favorably within the biotechnology sector, particularly due to the successful advancement of its non-viral gene therapy, detalimogene, which has received RMAT designation, indicating potential for expedited development in addressing non-muscle invasive bladder cancer. The company's recent protocol amendments have shown a significant impact on the six-month complete response (CR) rates, aligning them with best-in-class competitors while maintaining an overall superior profile due to its non-viral approach. With research and development expenses rising as the company intensifies its focus on manufacturing and clinical trial costs, enGene's progression in the LEGEND study and potential expansion of its target market are likely to support a positive financial outlook.
Bears say
enGene Holdings Inc. faces a negative outlook due to disappointing performance in its ongoing LEGEND trial, coupled with unexpected safety issues that could undermine investor confidence. Changes in regulatory requirements for non-muscle invasive bladder cancer (NMIBC) approvals and the emergence of unforeseen competition add further pressure, potentially delaying market entry and approval timelines that are critical for the company’s viability. Additionally, the necessity for higher-than-expected capital, likely leading to equity dilution, raises financial risks for existing shareholders as the company may need to pursue secondary offerings to fund its drug development initiatives.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares